Balaxi Pharmaceuticals (BALAXI) Q1 25/26 earnings summary

Executive summary

• Achieved Q1 FY26 revenue of ₹70.74 crore, up 8% year-over-year, driven by stable demand and operational execution.

• Gross profit margin remained strong at 44% in Q1 FY26, reflecting branded generics business strength.

• Net profit declined sharply to ₹0.29 crore from ₹6.48 crore in Q1 FY25 due to higher costs, one-time write-offs, and subsidiary ramp-up.

• Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.

• Commissioned first pharmaceutical formulation facility in Telangana, with stability batch production to start in early September 2025.

Financial highlights

• Q1 FY26 revenue grew 7.8% year-over-year to ₹70.74 crore; gross profit up 13.5% to ₹31.18 crore.

• Gross margin improved by 220 bps to 44.1%; EBITDA fell 58.8% to ₹4.15 crore, margin at 5.9%.

• PAT dropped 95.5% to ₹0.29 crore; EPS declined 95.9% to ₹0.05.

• Consolidated revenue for Q1 FY26 was ₹7,074.21 lakhs, up from ₹6,562.15 lakhs year-over-year.

• Consolidated net profit for the quarter was ₹821.85 lakhs, compared to ₹652.18 lakhs in Q1 FY25.

Outlook and guidance

• Focus on deepening presence in existing markets, expanding geographic footprint, and diversifying product portfolio.

• New manufacturing facility expected to enhance integration, margins, and access to new markets.

• Water validation and vendor qualification for the new Jadcherla plant expected to conclude by end of August 2025.

• Manufacturing test licence obtained; stability batch production to start in early September 2025.